What is Oncorus?
Oncorus is dedicated to pioneering next-generation viral immunotherapies aimed at transforming cancer patient outcomes. The company leverages two core platforms: its Herpes Simplex Virus (HSV) Platform for intratumoral (iTu) delivery, designed for enhanced systemic activity and reduced toxicity, and its selectively self-amplifying viral RNA (vRNA)/lipid nanoparticle (LNP) Immunotherapy Platform for intravenous (IV) administration. These innovative approaches are advancing a portfolio of treatments for indications with substantial unmet medical needs, positioning Oncorus at the forefront of oncological therapeutic development.
How much funding has Oncorus raised?
Oncorus has raised a total of $243.5M across 4 funding rounds:
Series A
$57M
Series B
$79.5M
Stock Offering
$87M
Debt
$20M
Series A (2016): $57M with participation from SunStates Fund, MPM Capital, Arkin Bio Ventures, Excelyrate Capital, Deerfield, Long March Investment Fund, and Celgene, Inc
Series B (2019): $79.5M led by IMM Investment, Shinhan Investment-Private Equity, Sphera Funds, Cowen Healthcare Investments, UTC Investment, Perceptive Advisors, SV Investment Corp, QUAD Investment Management, and Surveyor Capital
Stock Issuance/Offering (2020): $87M, investors not publicly disclosed
Debt (2022): $20M featuring K2 HealthVentures
Key Investors in Oncorus
K2 HealthVentures
K2 HealthVentures is an alternative investment firm specializing in flexible, long-term financing for life sciences and healthcare companies, driven by both profit and a commitment to improving patient lives.
MPM Capital
MPM Capital is a venture capital firm focused on early-stage investments in the biotechnology and life sciences sectors, aiming to convert scientific breakthroughs into impactful therapeutics.
Deerfield
Deerfield Management is an investment firm dedicated to advancing healthcare through strategic investments, data-driven insights, and philanthropic initiatives, supporting companies across the healthcare ecosystem.
What's next for Oncorus?
The substantial enterprise-level funding and recent strategic investment signal a critical growth phase for Oncorus. This capital infusion is expected to accelerate the advancement of its lead programs, ONCR-177 (HSV Platform) and ONCR-021 and ONCR-788 (vRNA Immunotherapy Platform), through IND-enabling studies and into clinical trials. The company's focus on novel RNA and oncolytic virus-based modalities suggests a strategic push towards realizing the full potential of these cutting-edge cancer treatments, aiming to capture significant market share in the rapidly evolving oncology therapeutics sector.
See full Oncorus company page
